How does tedizolid differ from linezolid regarding dosing, pharmacokinetics, antimicrobial spectrum, and safety profile?

Tedizolid vs Linezolid: Key Differences

Tedizolid offers significant advantages over linezolid through once-daily dosing (200 mg vs 600 mg twice daily), shorter treatment duration (6 days vs 10 days for skin infections), superior safety profile with less myelosuppression and gastrointestinal toxicity, and 4-8 fold greater in vitro potency against Gram-positive pathogens. 1, 2, 3

Dosing & Administration

Tedizolid:

• 200 mg once daily (oral or IV)
• 6-day course for acute bacterial skin and skin structure infections (ABSSSI)
• No dose adjustment needed for renal or hepatic impairment
• Can be given with or without food 1

Linezolid:

• 600 mg twice daily (oral or IV)
• 10-day course for ABSSSI
• Requires dose adjustment in specific populations
• Standard dosing for most infections 4

Pharmacokinetics

Tedizolid demonstrates superior pharmacokinetic properties:

• Bioavailability: ~91% (tedizolid) vs ~100% (linezolid)
• Half-life: ~12 hours (tedizolid) vs ~5 hours (linezolid)
• Protein binding: 70-90% (tedizolid) vs ~31% (linezolid)
• Metabolism: Primarily hepatic via sulfotransferases (SULT), not CYP450-dependent; 82% fecal elimination, 18% urinary 1, 2
• Volume of distribution: 67-80 L with excellent tissue penetration into adipose and skeletal muscle 1

The once-daily dosing of tedizolid is enabled by its longer half-life and sustained tissue concentrations, achieving steady-state within 3 days 1.

Antimicrobial Spectrum & Potency

Tedizolid is 4-8 fold more potent than linezolid against all Gram-positive pathogens 2, 5:

• MRSA: MIC₉₀ 0.5 mg/L (tedizolid) vs 2-4 mg/L (linezolid)
• Vancomycin-intermediate S. aureus (VISA): MIC₉₀ 0.5 mg/L vs 4 mg/L
• Daptomycin-non-susceptible S. aureus: MIC₉₀ 0.5 mg/L vs 2 mg/L
• VRE (E. faecalis): MIC₉₀ 0.25 mg/L vs 2 mg/L
• VRE (E. faecium): MIC₉₀ 1 mg/L vs 4 mg/L 5, 6

Critical advantage: Tedizolid retains activity against some linezolid-resistant strains harboring the cfr gene (MIC range 0.063-1 mg/L), though not all 6, 7. Both drugs share the same mechanism of action—inhibition of bacterial protein synthesis by binding 23S ribosomal RNA of the 50S subunit 2.

Tedizolid also demonstrates activity against anaerobes, particularly Bacteroides fragilis group (MIC₉₀ 1 mg/L vs 2-4 mg/L for linezolid), making it potentially useful in mixed infections 8.

Safety Profile

Tedizolid has a markedly superior safety profile, particularly for hematologic toxicity:

Myelosuppression

• Significantly lower rates of thrombocytopenia, neutropenia, and anemia compared to linezolid 3, 9
• In a 21-day study, tedizolid 200 mg showed minimal platelet suppression versus linezolid 600 mg twice daily 9
• The shorter 6-day course further reduces myelosuppression risk 10

Gastrointestinal Effects

• Lower incidence of nausea and vomiting with tedizolid 3
• Better overall GI tolerability in clinical trials 2, 3

Neuropathy

• Animal studies suggest lower propensity for peripheral neuropathy with long-term tedizolid use 2
• This is particularly relevant for MDR-TB treatment where linezolid causes frequent neurotoxicity (peripheral neuropathy, optic neuritis) 11

MAO Inhibition

• Both are weak, reversible MAO inhibitors
• Tedizolid shows no meaningful MAO-related interactions in tyramine and pseudoephedrine challenge studies, even at supratherapeutic doses 2
• No serotonergic activity in validated animal models 2

Cardiac Safety

• No QTc prolongation with tedizolid at therapeutic or supratherapeutic doses (1200 mg) 1

Clinical Efficacy

For ABSSSI, tedizolid (6 days) is non-inferior to linezolid (10 days):

• Early clinical response: 79.6% vs 80.5% (OR 0.96,95% CI 0.77-1.19) 3
• Similar efficacy across infection types: cellulitis/erysipelas, major cutaneous abscess, wound infections 10, 3
• MRSA microbiological cure: 95.2% vs 94% 3

Important caveat: In ventilated hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), tedizolid was non-inferior for day 28 mortality (28.1% vs 26.4%) but failed to demonstrate non-inferiority for clinical cure at test-of-cure (56.3% vs 63.9%; difference -7.6%, 97.5% CI -15.7 to 0.5) 12. This suggests tedizolid may not be optimal for severe pneumonia despite its potency.

Clinical Context & Practical Considerations

When to choose tedizolid over linezolid:

• ABSSSI requiring shorter treatment duration and improved adherence
• Patients at high risk for myelosuppression (baseline cytopenias, concurrent myelosuppressive drugs)
• Patients requiring prolonged oxazolidinone therapy where hematologic monitoring is challenging
• Infections with linezolid-resistant organisms harboring cfr gene (check susceptibility)
• Mixed infections involving MRSA and anaerobes 8

When linezolid remains preferred:

• MDR-TB treatment (extensive clinical experience, though tedizolid may emerge as alternative) 11
• VRE bacteremia (established efficacy data) 13
• CNS infections (established CSF penetration data for linezolid) 4
• Severe pneumonia/HABP/VABP (based on 12 trial results)

Common pitfall: Do not assume tedizolid is active against all linezolid-resistant strains. Resistance mechanisms involving ribosomal mutations (G2576T) may confer cross-resistance. The optrA and poxtA genes also mediate resistance to both agents 14.

Monitoring differences:

• Tedizolid: Less intensive hematologic monitoring required, though baseline and periodic CBCs still recommended
• Linezolid: Monthly CBCs mandatory, especially beyond 2 weeks of therapy; monthly screening for peripheral neuropathy 15, 11

The 6-day tedizolid regimen versus 10-day linezolid regimen represents a 40% reduction in treatment duration, improving patient convenience, reducing adverse event exposure, and potentially lowering healthcare costs while maintaining equivalent efficacy for ABSSSI 10, 3.